For a better experience please change your browser to CHROME, FIREFOX, OPERA or Internet Explorer.

New nasal spray being examined on girls who battle with low intercourse drive

A new nasal spray is being tested on hundreds of Australian Women struggling with low sex drive.

There is currently no approved treatment for women of childbearing potential to increase their lagging libido, which can result in significant stress.

“When women go to their doctor and say that they have lost interest in sex and it affects them and their relationship and well-being, they are often discharged too quickly,” said Susan Davis, professor of women’s health research at the Monash University program.

A new nasal spray is being tested on women struggling with low sex drive. (iStock)

“They tell them it’s because they work and have kids and they are stressed and not sleep,” she said.

Professor Davis is studying a molecule called BP101 to see if it can help treat women.

“This molecule works within the central brain pathways, particularly the so-called GABA pathway, which affects sexual behavior,” she said.

The spray delivers the synthetic peptide to the nerves in the nasal cavity and into the brain.

Around 480 women between the ages of 21 and 50 are hired in 10 locations across Australia.

A previous pilot study of up to 200 women was used to test the safety and effectiveness of the therapy.

“This molecule has been studied for safety,” said Professor Davis.

The latest development comes more than 20 years after the arrival of Viagra in Australia for the treatment of sexual dysfunction in men.

“We have treatments for male sexual dysfunction; we don’t have any for female sexual dysfunction in pre-menopausal women,” said Professor Davis.

New research by Monash researchers also uncovered the extent of the problem in Australian women.

A large study published last year found that around 10 percent of women between the ages of 18 and 39 had low levels of sexual desire, which resulted in significant stress.

The prevalence of sexual dysfunction escalates with age, with roughly every third woman between the ages of 40 and 65 having low sexual desire.

“The effects on their mental wellbeing are as severe as chronic conditions like type 2 diabetes or severe lower back pain,” said Professor Davis.

It was only last year that testosterone was approved for the treatment of postmenopausal women.

You can find more information about the trial version here Here.